Switch from anakinra to canakinumab in a severe case of CINCA syndrome

Int J Rheum Dis. 2016 Dec;19(12):1354-1356. doi: 10.1111/1756-185X.12800. Epub 2015 Nov 20.

Authors

Donato Rigante¹, Elena Verrecchia², Benedetto Falsini³, Raffaele Manna²

Affiliations

¹ Institute of Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy.
² Department of Internal Medicine, Periodic Fever Research Center, Università Cattolica Sacro Cuore, Rome, Italy.
³ Institute of Ophthalmology, Università Cattolica Sacro Cuore, Rome, Italy.

PMID: 26585548
DOI: 10.1111/1756-185X.12800

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / administration & dosage*
Antirheumatic Agents / adverse effects
Cryopyrin-Associated Periodic Syndromes / diagnosis
Cryopyrin-Associated Periodic Syndromes / drug therapy*
Cryopyrin-Associated Periodic Syndromes / immunology
Drug Substitution*
Humans
Interleukin 1 Receptor Antagonist Protein / administration & dosage*
Interleukin 1 Receptor Antagonist Protein / adverse effects
Male
Medication Adherence
Remission Induction
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Interleukin 1 Receptor Antagonist Protein
canakinumab